Antimicrobial Synergistic Effects of Linezolid and Vancomycin with a Small Synthesized 2-Mercaptobenzothiazole Derivative: A Challenge for MRSA Solving
Molecules · 2023
DOI: 10.3390/molecules28176348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Marilena Muraglia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari "A. Moro", Campus Universitario E. Quagliarello Via Orabona 4, 70125 Bar…. Hauptthemen laut MEDLINE: Vancomycin, Methicillin-Resistant Staphylococcus aureus. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methicillin-resistant Staphylococcus aureus (MRSA) emerged as one of the leading causes of persistent human infections and makes it difficult to treat bacteremia, especially with biofilm formation. In this work, we investigated the in vitro synergism between Linezolid (LNZ) and Vancomycin (VAN) with a 2-mercaptobenzothiazole derivative, resulting in a new small-molecule antibacterial compound that we named BTZ2e, on several clinical MRSA, MRSE (methicillin-resistant Staphylococcus epidermidis) and control (ATCC Collection) strains in their planktonic and biofilms cultures. The broth microdilution method evaluated the susceptibility of planktonic cells to each investigated antibiotic combined with BTZ2e. The biofilm’s metabolic activity was studied with the XTT reduction assay. As a result, in this study, biofilm formation was significantly suppressed by the BTZ2e treatment. In terms of minimal biofilm inhibitory concentration (MBIC), BTZ2e revealed an MBIC50 value of 32 μg/mL against methicillin-susceptible S. aureus (MSSA) and 16 μg/mL against methicillin-resistant S. aureus ATCC 43300 biofilms. An inhibition range of 32 μg/mL and 256 μg/mL was registered for the clinical isolates. Interestingly, a synergistic effect (FICI ≤ 0.5) was encountered for the combination of BTZ2e with LNZ and VAN on several planktonic and sessile strains. In particular, the best result against planktonic cells emerged as a result of the synergistic association between LNZ and BTZ2e, while against sessile cells, the best synergistic association resulted from VAN and BTZ2e. The consistent results indicate BTZ2e as a promising adjuvant against multi-resistant strains such as MRSA and MRSE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Farmacia-Scienze del Farmaco, Università Degli Studi di Bari "A. Moro", Campus Universitario E. Quagliarello Via Orabona 4, 70125 Bari, Italy.
- Dipartimento Interdisciplinare di Medicina, Università degli Studi di Bari "A. Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy.
ORCID-Profile: Marilena Muraglia, Antonio Rosato, Maria Lisa Clodoveo, Filomena Corbo
Zitieren
APA
Muraglia, M., Schiavone, B. I. P., Rosato, A., Clodoveo, M. L., & Corbo, F. (2023). Antimicrobial Synergistic Effects of Linezolid and Vancomycin with a Small Synthesized 2-Mercaptobenzothiazole Derivative: A Challenge for MRSA Solving. Molecules. https://doi.org/10.3390/molecules28176348
Vancouver
Muraglia M, Schiavone BIP, Rosato A, Clodoveo ML, Corbo F. Antimicrobial Synergistic Effects of Linezolid and Vancomycin with a Small Synthesized 2-Mercaptobenzothiazole Derivative: A Challenge for MRSA Solving. Molecules. 2023. doi:10.3390/molecules28176348
BibTeX
@article{Muraglia2023,
author = {Muraglia, Marilena and Schiavone, Brigida Immacolata Pia and Rosato, Antonio and Clodoveo, Maria Lisa and Corbo, Filomena},
title = {Antimicrobial Synergistic Effects of Linezolid and Vancomycin with a Small Synthesized 2-Mercaptobenzothiazole Derivative: A Challenge for MRSA Solving},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28176348}
}
EUVIMED